SCHEMBL8093682

SCHEMBL8093682

Cc1cc(OC2CCN(Cc3cccnc3CO)CC2)c2cccc(F)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 4/20 0.40
SCN9A Q15858 4/20 0.40
HTR2B P41595 5/20 0.40
HTR2C P28335 4/20 0.40
HTR3A P46098 4/20 0.40
HTR4 Q13639 4/20 0.40
HTR1A P08908 3/20 0.40
HTR7 P34969 3/20 0.40
KCNH2 Q12809 3/20 0.39
HTR1D P28221 2/20 0.38
HTR1B P28222 2/20 0.38
AR P10275 2/20 0.37
ADRB2 P07550 1/20 0.37
DRD2 P14416 1/20 0.37
HTR1F P30939 1/20 0.37
ADRA1B P35368 1/20 0.37
DRD3 P35462 1/20 0.37
HTR5A P47898 1/20 0.37
SCN1A P35498 2/20 0.37
SCN8A Q9UQD0 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8102279 0.89 HTR2B (0.42) SCN5ASCN9AHTR2BHTR2CHTR3A
SCHEMBL13945358 0.86 AR (0.40) SCN5ASCN9AHTR2BHTR2CHTR3A
SCHEMBL8095680 0.86 PDE4B (0.46) SCN5ASCN9AHTR2BHTR2CHTR3A
SCHEMBL8095861 0.82 KCNH2 (0.41) SCN5ASCN9AHTR2BHTR2CHTR3A
SCHEMBL8094095 0.82 GRIN1 (0.40) SCN5ASCN9AHTR2BHTR2CHTR3A
SCHEMBL8100325 0.82 JAK2 (0.39) SCN5ASCN9AHTR2BHTR2CHTR3A
SCHEMBL8091662 0.81 HRH1 (0.47) KCNH2ARSCN1ASCN8AKMT2A
SCHEMBL13945393 0.81 ADRB2 (0.51) ADRB2KDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL8088026 0.80 HTR2C (0.40) HTR2BHTR2CHTR3AHTR4HTR1A
SCHEMBL5526683 0.80 SCN1A (0.50) SCN5ASCN9AKCNH2SCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
WO-2009000085-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS TRPV1, TRPV2, TRPA1 SCN5A 113/4885SCN9A 125/4885HTR2B 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.